Home » Topics » Cancer, BioWorld Science

Cancer, BioWorld Science
RSS

XL-119 enters phase III trial in bile duct cancer

June 29, 2004

Target enrollment met in phase III study of Campath for B-CLL

June 29, 2004

IND accepted for phase II trials of Aplidin

June 29, 2004

Two series of MEK/c-Src kinase inhibitors claimed by AstraZeneca

June 29, 2004

New antiangiogenic agents in early development at Bayer

June 28, 2004

New phase II study of talabostat in CLL

June 28, 2004

Positive interim results from phase II trial of FK-228 in CTCL and PTCL

June 28, 2004

Synthetic adrenal steroid hormones protect from chemotherapy or radiation-induced myelodepression

June 28, 2004

Merck & Co. and Vertex collaborate on development of VX-680

June 28, 2004

CuraGen and Seattle Genetics sign ADC technology agreement

June 28, 2004

Popular Stories

Today's news in brief
BioWorld
IL-22 and TL1A, a robust couple for diagnosing hidradenitis suppurativa
BioWorld Science
Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with strong association with psoriasis and inflammatory bowel disease (IBD). While some...
Inhibiting the NLRP3 inflammasome for cognitive impairment, stroke
BioWorld Science
Vascular cognitive impairment and dementia (VCID) and cerebral small vessel disease are among the leading causes of dementia, where inflammation is known to play...
New mechanism of action identified for QC-6352
BioWorld Science
QC-6352 is a small molecule developed to inhibit the histone demethylase 4 (KDM4) that has shown potent antitumoral activity and which has a derivative named...
VST Bio’s VB-001 is neuroprotector after stroke
BioWorld Science
At the recent International Stroke Conference, researchers from VST Bio Corp. and Yale University presented preclinical data regarding VB-001, a monoclonal...